Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AMRN

Amarin Corp ADR

Nov 27 • 04:00PM ET

0.7768

Dollar change -0.0060
Percentage change -0.77	%

Healthcare • Drug Manufacturers - General • Ireland • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.13	Insider Own	0.44%	Shs Outstand	408.55M	Perf Week	-5.13%
Market Cap	317.36M	Forward P/E	-	EPS next Y	-0.16	Insider Trans	20.03%	Shs Float	406.74M	Perf Month	12.04%
Income	-52.56M	PEG	-	EPS next Q	-0.04	Inst Own	22.67%	Short Float / Ratio	3.91% / 10.13	Perf Quarter	-25.31%
Sales	323.77M	P/S	0.98	EPS this Y	35.75%	Inst Trans	-7.35%	Short Interest	15.89M	Perf Half Y	-34.72%
Book/sh	1.35	P/B	0.57	EPS next Y	2.40%	ROA	-6.02%	Target Price	1.31	Perf Year	-33.61%
Cash/sh	0.79	P/C	0.99	EPS next 5Y	38.90%	ROE	-9.21%	52W Range	0.65 - 2.23	Perf YTD	-35.80%
Dividend	-	P/FCF	-	EPS past 5Y	-0.85%	ROI	-9.35%	52W High	-65.17%	Beta	2.11
Dividend %	-	Quick Ratio	1.74	Sales past 5Y	22.90%	Gross Margin	56.18%	52W Low	19.32%	ATR	0.05
Employees	365	Current Ratio	2.69	Sales Q/Q	-26.30%	Oper. Margin	-19.13%	RSI (14)	51.27	Volatility	4.56% 6.94%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	-273.02%	Profit Margin	-16.23%	Rel Volume	0.77	Prev Close	0.78
Shortable	Yes	LT Debt/Eq	0.02	Earnings	Nov 01 BMO	Payout	-	Avg Volume	1.57M	Price	0.78
Recom	3.33	SMA20	4.77%	SMA50	-2.80%	SMA200	-35.31%	Volume	1,199,744	Change	-0.77%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Underweight
Oct-25-23	Downgrade	Jefferies	Buy → Hold	$3 → $1
Jan-06-23	Upgrade	Jefferies	Hold → Buy	$1.30 → $3
May-06-22	Downgrade	JP Morgan	Neutral → Underweight
May-05-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10 → $3
May-05-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $3
May-04-22	Downgrade	Northland Capital	Outperform → Market Perform
May-12-21	Downgrade	Goldman	Neutral → Sell	$6 → $5
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-26-20	Initiated	Piper Sandler	Overweight	$21
May-05-20	Initiated	Northland Capital	Outperform	$15
Mar-31-20	Upgrade	Oppenheimer	Underperform → Perform
Mar-31-20	Downgrade	Jefferies	Buy → Hold	$30 → $4
Mar-31-20	Downgrade	Goldman	Buy → Neutral
Mar-13-20	Upgrade	Goldman	Neutral → Buy	$28
Mar-02-20	Initiated	Cowen	Outperform	$23
Feb-18-20	Upgrade	Citigroup	Neutral → Buy	$27 → $24
Jan-06-20	Initiated	JP Morgan	Neutral	$22
Dec-16-19	Downgrade	Stifel	Buy → Hold
Nov-20-19	Initiated	Oppenheimer	Underperform	$7

Show Previous Ratings

Nov-12-23 09:00AM	New REDUCE-IT Analyses Show VASCEPA (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline (GlobeNewswire)
Nov-02-23 10:58AM	Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.47%
Nov-01-23 12:30PM	Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript (Motley Fool)
12:03PM	Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
09:30AM	Amarin (AMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:25AM	Loading…
09:25AM	Amarin Corp PLC (AMRN) Reports Q3 2023 Earnings: Net Revenues Down 27% Year-Over-Year (GuruFocus.com)
07:30AM	Amarin: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 12:00PM	Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer (GlobeNewswire)
Oct-26-23 08:00AM	Latest Research Evaluating VASCEPA /VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023 (GlobeNewswire)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey)
Oct-19-23 08:00AM	Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023 (GlobeNewswire)
Sep-12-23 08:00AM	Amarin to Present at the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-24-23 09:29AM	11 Best Long-Term Penny Stocks to Buy Now (Insider Monkey)
Aug-19-23 11:22AM	Buffett goes big on homebuilders: Insider trades & hedge funds weekly (Investing.com)
04:05PM	Loading…
Aug-09-23 04:05PM	Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy (GlobeNewswire)
Aug-08-23 07:00AM	Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel (GlobeNewswire)
Aug-07-23 07:00AM	Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1) (GlobeNewswire)
Aug-03-23 11:22AM	Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-02-23 07:33AM	Amarin: Q2 Earnings Snapshot (AP Finance)
07:11AM	Amarin Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 08:00AM	Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea (GlobeNewswire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey) +6.25%
Jul-26-23 08:00AM	Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress (GlobeNewswire)
Jul-25-23 04:05PM	Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain (GlobeNewswire)
Jul-20-23 08:00AM	Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt (GlobeNewswire)
Jul-19-23 12:58PM	Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss (Zacks) -24.48%
11:19AM	Why Amarin Stock Is Sinking Today (Motley Fool)
Jul-18-23 04:16PM	Amarin Appoints Patrick Holt as President and Chief Executive Officer (GlobeNewswire) +9.16%
04:15PM	Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally (GlobeNewswire)
11:43AM	Loading…
Jul-05-23 11:43AM	Amarin (NASDAQ:AMRN) shareholders have endured a 83% loss from investing in the stock three years ago (Simply Wall St.)
Jun-21-23 09:00AM	Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA) (GlobeNewswire)
Jun-08-23 11:07AM	Investors Aren't Buying Amarin Corporation plc's (NASDAQ:AMRN) Revenues (Simply Wall St.)
Jun-01-23 04:30PM	Amarin to Present at Two Upcoming Investor Conferences (GlobeNewswire)
06:00AM	Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China (GlobeNewswire)
May-23-23 09:50AM	3 Biotech Stocks to Avoid Like the Plague (InvestorPlace)
May-12-23 11:00AM	Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events (GlobeNewswire)
May-03-23 02:00PM	Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript (Motley Fool)
01:47PM	Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall (Zacks)
07:41AM	Amarin: Q1 Earnings Snapshot (AP Finance)
07:00AM	Amarin Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-02-23 01:32PM	Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More (Zacks)
Apr-19-23 08:00AM	Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 (GlobeNewswire)
Apr-17-23 07:00AM	Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver OConnor to Companys Board of Directors (GlobeNewswire)
Apr-13-23 10:18AM	Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation (Simply Wall St.)
Apr-12-23 09:18AM	Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock? (Zacks)
Apr-04-23 03:53PM	Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today (Motley Fool)
08:00AM	Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health (GlobeNewswire)
Mar-16-23 08:00AM	Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl) (GlobeNewswire) +7.24%
Mar-06-23 04:05PM	Amarin Announces Board Departures (GlobeNewswire)
09:37AM	Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome (Benzinga)
08:00AM	Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC (GlobeNewswire)
Mar-05-23 10:21AM	Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event (GlobeNewswire)
Mar-03-23 11:09AM	Amarin Corporation plc (NASDAQ:AMRN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-02-23 01:23PM	Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates (Zacks) -5.34%
11:44AM	Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales (Zacks)
05:55AM	Amarin Full Year 2022 Earnings: US$0.26 loss per share (vs US$0.02 profit in FY 2021) (Simply Wall St.)
Mar-01-23 11:02AM	Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up (Zacks)
11:00AM	Amarin Plc (AMRN) Q4 2022 Earnings Call Transcript (Motley Fool)
07:00AM	Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-23 11:11AM	Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales (Zacks) +10.33%
10:39AM	Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide (Business Wire)
10:38AM	Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders (GlobeNewswire)
08:00AM	Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand (GlobeNewswire)
Feb-27-23 04:29PM	Amarin Sets the Record Straight on Sarissas Latest Misstatements (GlobeNewswire)
08:00AM	Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC (GlobeNewswire)
07:15AM	Sarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives (Business Wire)
Feb-24-23 11:52AM	Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4 (Zacks)
Feb-22-23 04:50PM	Hikma accuses Amarin of suppressing generic versions of heart pill (Reuters)
08:00AM	Amarin to Present at Cowen's 43rd Annual Health Care Conference (GlobeNewswire)
Feb-21-23 08:30AM	Sarissa Capital Reminds Amarin Shareholders Today Is the Last Day to Vote "FOR" Change (Business Wire)
08:00AM	Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023 (GlobeNewswire)
Feb-20-23 01:00PM	Sarissa Capital Urges Amarin Shareholders to Vote "FOR" Necessary Change (Business Wire)
Feb-17-23 09:03AM	Amarin Urges Shareholders to Vote Against Sarissas Harmful Proposals at Upcoming General Meeting IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE (GlobeNewswire)
07:30AM	Sarissa Capital Urges Amarin Shareholders to Vote for Change and Remake Amarin for Shareholders (Business Wire)
Feb-16-23 04:05PM	Sarissa Capital Blasts Amarins Repeated False Statements; Clearly Amarin Will Say Anything to Keep Sarissa Off the Board (Business Wire)
12:34PM	Leading Independent Proxy Firm ISS Joins Glass Lewis in Recommending that Amarin Shareholders Vote AGAINST Sarissas Value-Destructive Proposals (GlobeNewswire)
09:44AM	Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards (GlobeNewswire)
Feb-15-23 04:29PM	Sarissa Capital Uncovers That Amarins Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So (Business Wire)
Feb-14-23 05:09PM	Sarissa Capital Disappointed That Amarin Webcast Continues Boards Defense of Poor Results and Lack of Accountability (Business Wire)
09:55AM	Amarin (AMRN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Feb-13-23 07:47PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote AGAINST All of Sarissas Proposals (GlobeNewswire)
09:40AM	Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:00AM	Sarissa Capital Warns of Amarins Expensive Attempts to Switch Votes by Inundating Shareholders With White Proxy Cards (Business Wire)
08:00AM	Amarin Shareholders Invited to Webcast with Board and Management Team (GlobeNewswire)
Feb-09-23 05:27PM	Sarissa Capital Does Not Believe Amarin Cares About Shareholders (Business Wire)
08:00AM	Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card AGAINST Sarissas Harmful Proposals (GlobeNewswire)
Feb-07-23 04:35PM	Sarissa Capital Highlights Amarins Inaccurate and Misleading Statements (Business Wire) +12.89%
Feb-06-23 08:00AM	Amarin Mails Letter to Shareholders Highlighting Sarissas Myths vs. The Facts (GlobeNewswire)
Feb-03-23 05:16PM	Sarissa Capital Highlights Amarins Disregard for Shareholder Interests and Urges Shareholders to Vote the BLUE Proxy Card for Change at Amarin (Business Wire)
Feb-02-23 04:30PM	Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership (GlobeNewswire)
Feb-01-23 04:09PM	Sarissa Capital Urges Amarin Shareholders to Vote the Blue Card by February 22 to Fix Amarin for the Benefit of Shareholders (Business Wire)
Jan-31-23 08:24AM	Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders (GlobeNewswire)
Jan-27-23 06:35PM	Amarin and ViewRay Stock See Action From Activist Investors (Barrons.com)
08:45AM	Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand (GlobeNewswire)
08:00AM	Amarin to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-23-23 11:01AM	Amarin Corporation (AMRN) Down 13% in One Week: Here's Why (Zacks)
Jan-20-23 10:04AM	Why Amarin Stock Tumbled This Week (Motley Fool)
Jan-19-23 09:15PM	3 Penny Stocks to Sell in January Before They Peter Out (InvestorPlace)
12:04PM	Amarin Calls Activist Investor, Largest Shareholder Sarissa's Statement 'Inaccurate, Misleading' (Benzinga)

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Holt Patrick	President and CEO	Aug 16	Buy	1.04	300,000	312,315	300,000	Aug 16 07:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMRN

Amarin Corp ADR

Upgrade your FINVIZ experience